Health Canada stepped up to the plate back in December with a Notice of Intent to amend the Food and Drug Regulations and the Narcotic Control Regulations to restore…
Mushrooms
We’re living in interesting times and I mean that in the Chinese curse kind of way. We can’t seem to stop to catch our breath when it comes to…
MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals…
$41.189M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has received approval from Health Canada for a Phase 2 clinical trial utilizing the Company’s standardized natural psilocybin…
The Bare Naked Ladies made “if I had a million dollars,” famous, as they tunefully explained what they would do with their riches. However, in the post-crisis everything bubble,…
Just micro-dosed a few minutes ago to stay on theme for this 2022 technical outlook. Psychedelics. 2021 was the year I was introduced to the benefits of psychedelics. Mind…
Quite the price action on Filament Health yesterday. The company is all about paving the way for the first ever natural psychedelic drug. Filament Health Corp. operates as a…
Psychedelics have showed tremendous potential in treating neurological conditions such as major depressive disorder, PTSD, ALS, and generalized anxiety. Investors jumped on the opportunity, sending market values skyrocketing. It’s…
The world’s first psychedelic ETF, PSYK, is an industry bellwether which indicates the psychedelics space continues to take a drubbing since the ETF launched in January. The fund closed…
The psychedelics space is loaded with over-valued unicorns and also-rans, making it difficult for investors to find real growth opportunities. Here are some companies in the sector that have…